Arcoxia Advisory Committee Will Be Missing Key Participants From 2005 COX-2 Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
Many of the key panelists during the 2005 advisory committee review of COX-2 inhibitor cardiovascular safety will not be participating in the Arthritis Advisory Committee's April 12 review of Merck's Vioxx follow-on Arcoxia
You may also be interested in...
FDA Sets High Bar For Approval Of Merck’s COX-2 Arcoxia
FDA’s Arthritis Drugs Advisory Committee will review Merck’s Vioxx follow-on etoricoxib during an April 12 meeting.
FDA Sets High Bar For Approval Of Merck’s COX-2 Arcoxia
FDA’s Arthritis Drugs Advisory Committee will review Merck’s Vioxx follow-on etoricoxib during an April 12 meeting.
Advisory Committee Conflict Of Interest Policy Simplified In Draft Guidance
FDA presents a consolidated, step-by-step policy to determine eligibility of possible advisory committee participants.